Dr. Matteo Simonelli is currently the Head of the Early-Phase Drug Development in Solid Tumors and Neuro-Oncology at the IRCCS Humanitas Research Hospital. He is also part of the Faculty of Humanitas University, as an Assistant Professor of Medical Oncology at the Department of Biomedical Sciences. In 2022, he became the Head of the Humanitas Tumor Molecular Board Scientific Committee. He has a long-standing interest in the field of clinical and translational cancer research, being the Principal Investigator of several international, multicenter Phase 1 trials, investigating the safety and activity of the most innovative anticancer therapeutic approaches for solid malignancies particularly in the field of Immunotherapy and Molecular Targeted Therapies. Additionally, he is a member of the steering/data monitoring committee for international clinical research programs. In the context of Neuro-oncology, he is the Principal Investigator of several clinical studies investigating new therapeutic modalities in gliomas. Since 2019 he has been a member of the Writing Committee of the national guidelines for the treatment of brain tumors. He is an active member of the European Society for Medical Oncology (ESMO), Associazione Italiana Oncologia Medica AIOM, the European Organization for Research and Treatment (EORTC) Brain Tumor Group, and the European Association of Neuro-Oncology (EANO).